Matthieu Wargny1,2, Louis Potier3,4, Pierre Gourdy5,6, Matthieu Pichelin1, Coralie Amadou7,8, Pierre-Yves Benhamou9,10, Jean-Baptiste Bonnet11, Lyse Bordier12, Olivier Bourron13,14,15,16, Claude Chaumeil17, Nicolas Chevalier18, Patrice Darmon19,20, Blandine Delenne21, Delphine Demarsy22, Marie Dumas23, Olivier Dupuy24, Anna Flaus-Furmaniuk25, Jean-François Gautier4,26, Anne-Marie Guedj27, Nathalie Jeandidier28, Etienne Larger29, Jean-Philippe Le Berre30, Myriam Lungo31, Nathanaëlle Montanier32, Philippe Moulin33, Françoise Plat34, Vincent Rigalleau35, René Robert36, Dominique Seret-Bégué37, Pierre Sérusclat38, Sarra Smati1, Jean-François Thébaut17, Blandine Tramunt5,6, Camille Vatier39,40, Fritz-Line Velayoudom41, Bruno Vergès42, Patrice Winiszewski43, Audrey Zabulon44, Pierre-Antoine Gourraud2, Ronan Roussel3,4, Bertrand Cariou45, Samy Hadjadj46. 1. l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Nantes, France. 2. CHU de Nantes, Inserm, CIC 1413, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des Données, Nantes, France. 3. Département d'Endocrinologie, Diabétologie et Nutrition, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Paris, France. 4. Centre de Recherche des Cordeliers, Inserm, U-1138, Université de Paris, Paris, France. 5. Département d'Endocrinologie, Diabétologie et Nutrition, CHU Toulouse, Toulouse, France. 6. Institut des Maladies Métaboliques et Cardiovasculaires, UMR1048 Inserm/UPS, Université de Toulouse, Toulouse, France. 7. Département de Diabétologie, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France. 8. Université Paris-Saclay, Paris, France. 9. Service Endocrinologie-Diabétologie-Nutrition, CHU Grenoble, Grenoble, France. 10. University Grenoble-Alpes, Grenoble, France. 11. Département d'Endocrinologie, Diabète, Nutrition et CIC Inserm 1411, CHU de Montpellier, Montpellier, France. 12. Département de Diabétologie, H.I.A. Begin, Saint Mandé, France. 13. Sorbonne Université, Paris, France. 14. Assistance Publique Hôpitaux de Paris, Département de Diabétologie, CHU La Pitié Salpêtrière-Charles Foix, Paris, France. 15. Centre de Recherche des Cordeliers, Inserm, U-1138, Paris, France. 16. Institute of Cardiometabolism and Nutrition ICAN, Paris, France. 17. Fédération Française des Diabétiques (FFD), Paris, France. 18. Université Côte d'Azur, CHU, Inserm U1065, C3M, Nice, France. 19. Service d'Endocrinologie, Maladies Métaboliques et Nutrition, Hôpital de la Conception, Assistance Publique Hôpitaux de Marseille, Marseille, France. 20. C2VN, Inserm, INRA, Aix Marseille Université, Marseille, France. 21. Service d'Endocrinologie, Diabétologie et Maladies Métaboliques, Centre Hospitalier d'Aix-en-Provence, Aix-en-Provence, France. 22. Service Endocrinologie-Diabétologie, Centre Hospitalier de la Côte Basque, Bayonne, France. 23. Service Endocrinologie-Diabétologie, Hôpital Saint Vincent de Paul Lille, Lille, France. 24. Service de Diabétologie Endocrinologie, Hôpital Paris Saint-Joseph, Paris, France. 25. Service d'Endocrinologie - Diabétologie, Site Felix Guyon, CHU de la Réunion, Saint-Denis de la Réunion, France. 26. Service de Diabétologie et d'Endocrinologie, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France. 27. Service des Maladies Métaboliques et Endocriniennes, CHU de Nîmes, Université de Montpellier, Nîmes, France. 28. Service d'Endocrinologie, Diabétologie et Nutrition, Hôpitaux Universitaires de Strasbourg, UdS, Strasbourg, France. 29. Service de Diabétologie et Immunologie Clinique, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Centre-Université de Paris, Paris, France. 30. Service de Diabétologie et d'Endocrinologie, Médipôle, Villeurbanne, France. 31. Service d'Endocrinologie et de Diabétologie, Centre Hospitalier de Bastia, Bastia, France. 32. Service d'Endocrinologie, Centre Hospitalier du Forez, Montbrison, France. 33. Hôpital Cardiovasculaire Louis Pradel, Hospices Civils de Lyon, Inserm UMR 1060 Carmen, Université Claude Bernard Lyon 1, Lyon, France. 34. Service d'Endocrinologie et Maladies Métaboliques, Centre Hospitalier d'Avignon, Avignon, France. 35. Endocrinology-Nutrition Department, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France. 36. Université de Poitiers; CIC Inserm 1402; Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France. 37. Service de Diabétologie, Endocrinologie et Nutrition, Centre Hospitalier de Gonesse, Gonesse, France. 38. Service d'Endocrinologie, Diabétologie et Maladies Métaboliques, Groupe Hospitalier Mutualiste Les Portes du Sud, Venissieux, France. 39. Assistance Publique Hôpitaux de Paris, Saint-Antoine Hospital, Reference Center of Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Department of Endocrinology, Paris, France. 40. Sorbonne University, Inserm UMRS 938, Saint-Antoine Research Center, Paris, France. 41. Service d'Endocrinologie, Diabétologie et Métabolisme, Centre Hospitalier Universitaire de Guadeloupe, Pointe-à-Pitre, France. 42. Service Endocrinologie, Diabétologie et Maladies Métaboliques, Hôpital du Bocage, Dijon, France. 43. Service d'Endocrinologie, Diabétologie et Nutrition, Hôpital Nord Franche-Comté, Trévenans, France. 44. Service d'Endocrinologie et Diabétologie, CHU de Martinique, Fort-de-France, France. 45. l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Nantes, France. bertrand.cariou@univ-nantes.fr. 46. l'institut du thorax, Inserm, CNRS, UNIV Nantes, CHU Nantes, Nantes, France. samy.hadjadj@univ-nantes.fr.
Abstract
AIMS/HYPOTHESIS: This is an update of the results from the previous report of the CORONADO (Coronavirus SARS-CoV-2 and Diabetes Outcomes) study, which aims to describe the outcomes and prognostic factors in patients with diabetes hospitalised for coronavirus disease-2019 (COVID-19). METHODS: The CORONADO initiative is a French nationwide multicentre study of patients with diabetes hospitalised for COVID-19 with a 28-day follow-up. The patients were screened after hospital admission from 10 March to 10 April 2020. We mainly focused on hospital discharge and death within 28 days. RESULTS: We included 2796 participants: 63.7% men, mean age 69.7 ± 13.2 years, median BMI (25th-75th percentile) 28.4 (25.0-32.4) kg/m2. Microvascular and macrovascular diabetic complications were found in 44.2% and 38.6% of participants, respectively. Within 28 days, 1404 (50.2%; 95% CI 48.3%, 52.1%) were discharged from hospital with a median duration of hospital stay of 9 (5-14) days, while 577 participants died (20.6%; 95% CI 19.2%, 22.2%). In multivariable models, younger age, routine metformin therapy and longer symptom duration on admission were positively associated with discharge. History of microvascular complications, anticoagulant routine therapy, dyspnoea on admission, and higher aspartate aminotransferase, white cell count and C-reactive protein levels were associated with a reduced chance of discharge. Factors associated with death within 28 days mirrored those associated with discharge, and also included routine treatment by insulin and statin as deleterious factors. CONCLUSIONS/ INTERPRETATION: In patients with diabetes hospitalised for COVID-19, we established prognostic factors for hospital discharge and death that could help clinicians in this pandemic period. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT04324736.
AIMS/HYPOTHESIS: This is an update of the results from the previous report of the CORONADO (CoronavirusSARS-CoV-2 and Diabetes Outcomes) study, which aims to describe the outcomes and prognostic factors in patients with diabetes hospitalised for coronavirus disease-2019 (COVID-19). METHODS: The CORONADO initiative is a French nationwide multicentre study of patients with diabetes hospitalised for COVID-19 with a 28-day follow-up. The patients were screened after hospital admission from 10 March to 10 April 2020. We mainly focused on hospital discharge and death within 28 days. RESULTS: We included 2796 participants: 63.7% men, mean age 69.7 ± 13.2 years, median BMI (25th-75th percentile) 28.4 (25.0-32.4) kg/m2. Microvascular and macrovascular diabetic complications were found in 44.2% and 38.6% of participants, respectively. Within 28 days, 1404 (50.2%; 95% CI 48.3%, 52.1%) were discharged from hospital with a median duration of hospital stay of 9 (5-14) days, while 577 participantsdied (20.6%; 95% CI 19.2%, 22.2%). In multivariable models, younger age, routine metformin therapy and longer symptom duration on admission were positively associated with discharge. History of microvascular complications, anticoagulant routine therapy, dyspnoea on admission, and higher aspartate aminotransferase, white cell count and C-reactive protein levels were associated with a reduced chance of discharge. Factors associated with death within 28 days mirrored those associated with discharge, and also included routine treatment by insulin and statin as deleterious factors. CONCLUSIONS/ INTERPRETATION: In patients with diabetes hospitalised for COVID-19, we established prognostic factors for hospital discharge and death that could help clinicians in this pandemic period. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT04324736.
Authors: J K Yang; Y Feng; M Y Yuan; S Y Yuan; H J Fu; B Y Wu; G Z Sun; G R Yang; X L Zhang; L Wang; X Xu; X P Xu; J C N Chan Journal: Diabet Med Date: 2006-06 Impact factor: 4.359
Authors: Giacomo Grasselli; Alberto Zangrillo; Alberto Zanella; Massimo Antonelli; Luca Cabrini; Antonio Castelli; Danilo Cereda; Antonio Coluccello; Giuseppe Foti; Roberto Fumagalli; Giorgio Iotti; Nicola Latronico; Luca Lorini; Stefano Merler; Giuseppe Natalini; Alessandra Piatti; Marco Vito Ranieri; Anna Mara Scandroglio; Enrico Storti; Maurizio Cecconi; Antonio Pesenti Journal: JAMA Date: 2020-04-28 Impact factor: 56.272
Authors: Michael G Argenziano; Samuel L Bruce; Cody L Slater; Jonathan R Tiao; Matthew R Baldwin; R Graham Barr; Bernard P Chang; Katherine H Chau; Justin J Choi; Nicholas Gavin; Parag Goyal; Angela M Mills; Ashmi A Patel; Marie-Laure S Romney; Monika M Safford; Neil W Schluger; Soumitra Sengupta; Magdalena E Sobieszczyk; Jason E Zucker; Paul A Asadourian; Fletcher M Bell; Rebekah Boyd; Matthew F Cohen; MacAlistair I Colquhoun; Lucy A Colville; Joseph H de Jonge; Lyle B Dershowitz; Shirin A Dey; Katherine A Eiseman; Zachary P Girvin; Daniella T Goni; Amro A Harb; Nicholas Herzik; Sarah Householder; Lara E Karaaslan; Heather Lee; Evan Lieberman; Andrew Ling; Ree Lu; Arthur Y Shou; Alexander C Sisti; Zachary E Snow; Colin P Sperring; Yuqing Xiong; Henry W Zhou; Karthik Natarajan; George Hripcsak; Ruijun Chen Journal: BMJ Date: 2020-05-29
Authors: Pavan K Bhatraju; Bijan J Ghassemieh; Michelle Nichols; Richard Kim; Keith R Jerome; Arun K Nalla; Alexander L Greninger; Sudhakar Pipavath; Mark M Wurfel; Laura Evans; Patricia A Kritek; T Eoin West; Andrew Luks; Anthony Gerbino; Chris R Dale; Jason D Goldman; Shane O'Mahony; Carmen Mikacenic Journal: N Engl J Med Date: 2020-03-30 Impact factor: 91.245
Authors: L E Joensen; K P Madsen; L Holm; K A Nielsen; M H Rod; A A Petersen; N H Rod; I Willaing Journal: Diabet Med Date: 2020-05-29 Impact factor: 4.213
Authors: Hsin-Chieh Yeh; Jennifer L Kraschnewski; Lan Kong; Erik B Lehman; Emily S Heilbrunn; Pamela Williams; Jennifer M Poger; Erica Francis; Cindy L Bryce Journal: BMJ Open Diabetes Res Care Date: 2022-06
Authors: Isabel Boden; Miguel O Bernabeu; Baljean Dhillon; David A Dorward; Ian MacCormick; Roly Megaw; Claire Tochel Journal: Diabetes Res Clin Pract Date: 2022-04-05 Impact factor: 8.180